Proximie has announced a new partnership with HistoSonics to support the rollout of the Edison Histotripsy System across hospitals and surgical centres in the US, offering a non-invasive treatment option for liver tumours.
The collaboration integrates Proximie’s intelligent operating room platform with HistoSonics’ focused ultrasound therapy system.
Proximie’s cloud-based technology enables real-time connectivity, data capture and AI-driven insights, allowing HistoSonics’ medical experts to guide surgeons remotely during procedures.
Dr Nadine Hachach-Haram, Founder and CEO of Proximie, said: “We are thrilled to announce our partnership with HistoSonics, driving the rollout of the cutting-edge Histotripsy System while making a tangible impact on outcomes for those suffering from liver tumors.”
Mike Blue, President and CEO of HistoSonics, added: “Our partnership with Proximie represents our commitment to partner with world leaders in their respective domains, providing our customers with the best technology solutions possible.”
Initial rollout regions include Chicago, Colorado, Florida, Louisiana, Seattle and Southern California. The partnership aims to enhance surgical productivity and improve recovery times for patients.
Dr Kevin Burns, Chief of Interventional Radiology at Providence Mission Hospital, said: “HistoSonics’ Edison Histotripsy System has drastically improved outcomes for our patients suffering with liver tumors. The system’s ability to destroy tumors via non-thermal, non-invasive, personalized therapy significantly reduces recovery times.”
Nearly 300,000 patients in the US are diagnosed with liver tumours each year, many of which are metastatic. The five-year survival rate for primary liver cancer remains below 18 percent, highlighting the urgent need for innovative treatment approaches.
The partnership builds on Proximie’s recent collaborations with Olympus Corporation and Distalmotion, reinforcing its role in advancing digital surge.
